When developing new medicines, drugmakers typically try to make treatments that are more effective, durable or safer than what’s already available.
If they’re lucky, they can hit on something that meets at least one of those goals. Rampart Bioscience, a new biotechnology company eyeing a way to make better DNA-based medicines, is striving to hit all three.
Headquartered in La Jolla, California, Rampart emerged from stealth Tuesday with $85 million in new funding to develop its lead program for a rare inherited condition known as hypophosphatasia.
